Glycogen Synthase Kinase 3β in Pancreatic Cancer and its Implications in Chemotherapy and Radiation Therapy
- *Corresponding Author:
- Meredith A. Morgan
Department of Radiation Oncology
University of Michigan Medical School
Room 4326B Medical Sciences I, Ann Arbor, MI 48109-5637, USA
E-mail: [email protected]
Received date: June 06, 2013; Accepted date: August 09, 2013; Published date: August 16, 2013
Citation: Zhang Q, Bhojani MS, Josef EB, Spalding AC, Kuick R, et al. (2013) Glycogen Synthase Kinase 3β in Pancreatic Cancer and its Implications in Chemotherapy and Radiation Therapy. J Carcinogene Mutagene 4:147. doi: 10.4172/2157-2518.1000147
Copyright: © 2013 Zhang Q, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Pancreatic cancer is a highly lethal disease with a poor prognosis characterized by local and systemic disease progression. Both radiation and chemotherapy play important roles in the management of this disease. However, in order to improve standard therapy many molecularly targeted agents are being developed. Glycogen synthase kinase 3β (GSK3β) participates in a multitude of cellular processes and is a newly proposed therapeutic target in pancreatic cancer. This review will discuss both the oncogenic and tumor suppressor functions of GSK3β in pancreatic cancer with an emphasis on the roles of GSK3β in tumor cell survival and sensitivity to radiation and chemotherapy.